Chronic Constipation Treatment Market Report 2025 (Global Edition)

Global Chronic Constipation Treatment Market Report 2025 Market Size Split by Type (Normal-transit constipation, Slow-transit constipation, Others), by End-users (Hospitals, Homecare, Specialty Clinic...

Chronic Constipation Treatment Market Report Description

We have various report editions of Chronic Constipation Treatment Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.

Impact of Tariff Trumph on Pharmaceuticals Industry

The reintroduction of tariffs under President Trump’s “Liberation Day Tariffs” in April 2025 has created significant disruption in global pharmaceutical trade. These tariffs, ranging from 10% to 46%, specifically target pharmaceutical products, APIs (active pharmaceutical ingredients), medical packaging, and machinery from key manufacturers in China and India. This has led to increased production costs, supply chain delays, and regulatory challenges for U.S.-based pharmaceutical companies.

The tariffs have particularly impacted generic drug manufacturers, who rely heavily on APIs from China and India. Biopharmaceuticals and vaccines are also feeling the pressure, with tariffs on critical materials like bioproduction media and cold-chain packaging raising costs by up to 25%. Similarly, contract manufacturing organizations (CMOs) are grappling with the need to identify new suppliers and adjust production plans to mitigate rising costs.

Foreign governments, including the European Union, have retaliated with tariffs on U.S. pharmaceutical exports, further complicating global trade. Clinical trials are also impacted, as tariffs on drugs and diagnostic kits delay trial timelines.

Market research is increasingly crucial for navigating these challenges. By providing real-time data on API pricing, supplier reliability, and tariff impact, pharmaceutical firms can make informed decisions on sourcing, compliance, and investment strategies. This data-driven approach helps mitigate risks, optimize supply chains, and identify alternative manufacturing hubs to offset tariff-related disruptions.

Overall, market research is essential for pharmaceutical companies to adapt to the new tariff landscape, enabling them to maintain competitive advantage and navigate global trade dynamics effectively.

Chronic Constipation Treatment Market Insights Video

Competitive Landscape of Chronic Constipation Treatment Market

A trend of innovation and collaboration marks the competitive landscape. Research and development efforts focus on developing novel mechanisms of action, such as guanylate cyclase-C agonists and serotonin-4 (5-HT4) receptor agonists, to enhance treatment efficacy and patient outcomes. The competitive landscape also faces challenges such as patent expirations, generic competition, and the need for differentiated products. Companies must invest in research and development to stay ahead in this rapidly evolving field. The Chronic Constipation Treatment Market is expected to continue evolving with the introduction of innovative therapies, personalized treatment approaches, and increased patient education.

Chronic Constipation Treatment Industry News

• May 2022: EA Pharma and Mochida Pharmaceutical have jointly introduced "MOVICOL HD" in Japan, a new treatment for chronic constipation.

(Source:www.highcpmrevenuegate.com/bsfxjwvd?key=9ca601a9f47c735df76d5ca46fa26a66&submetric=20300687)

• April 2022: Ardelyx, Inc. obtained approval from the United States Food and Drug Administration (USFDA) for IBSRELA. This innovation is an NHE3 inhibitor crafted to address irritable bowel syndrome with constipation (IBS-C), specifically in adults.

(Source:ir.ardelyx.com/news-releases/news-release-details/ardelyx-receives-fda-approval-ibsrelar-tenapanor-nhe3-sodium)

• March 2021: Knight Therapeutics Inc. unveiled the commencement of IBSRELA (tenapanor) in the Canadian market. This pioneering treatment is designed to exclusively alleviate irritable bowel syndrome with constipation (IBS-C) in adults. The company possesses the exclusive privilege to market IBSRELA in Canada, pursuant to an agreement established with Ardelyx, Inc.

(Source:www.globenewswire.com/en/news-release/2021/03/02/2184801/0/en/Knight-Therapeutics-Announces-Canadian-Commercial-Launch-of-IBSRELA-New-Innovative-Treatment-for-Irritable-Bowel-Syndrome-with-Constipation.html)

Top Companies Market Share in Chronic Constipation Treatment Industry: (In no particular order of Rank)

• Takeda Pharmaceuticals
• Ironwood Pharmaceuticals
• Synergy Pharmaceuticals
• Salix Pharmaceuticals
• Shire Pharmaceuticals
• Allergan
• Pfizer
• Sucampo Pharmaceuticals
• Norgine
• Teva Pharmaceuticals
• 5 AM Ventures
• Shionogi
• Theravance Biopharma
• Progenity Inc.
• Ardelyx
• Renexxion
• RedHill Biopharma
• Ferring Pharmaceuticals
• Synthetic Biologics
• Progenics Pharmaceuticals
• Confidential Data
• Access The Paid Version
• Data Hidden

*List of Second Tier Companies, List of Third Tier/ Start-up Companies (Inquire with sales executive) Request Any Company Profile for Preview Purpose OR Data Validation!

If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.

North America Chronic Constipation Treatment Dominates the Market in 2022

According to Cognitive Market Research, North America dominated the market in 2022 and accounted for a share of more than 36% of the global revenue due to several variables. Due to several contributing factors, North America has secured the largest market share in the Chronic Constipation Treatment Market. The region benefits from advanced healthcare infrastructure, high healthcare expenditure, and a well-established pharmaceutical industry. These elements facilitate developing, approving, and distributing of a wide range of chronic constipation treatments. Additionally, the aging population in North America has led to an increased prevalence of chronic constipation cases, driving the demand for effective treatments. Furthermore, a higher awareness of healthcare, greater accessibility to medical services, and favorable reimbursement policies in certain North American countries contribute to market growth.

Moreover, the region's robust research and development initiatives focus on introducing innovative therapies and improving existing treatment options. This innovation attracts both local and international market players, fostering competition and contributing to expanding the market share. Overall, the combination of advanced healthcare infrastructure, a growing aging population, awareness about chronic constipation, and continuous research efforts collectively positions North America as a dominant player in the Chronic Constipation Treatment Market.

Due to several factors, Europe is witnessing rapid growth in the Chronic Constipation Treatment Market. The region has a well-developed healthcare system, increasing awareness about chronic constipation, and a growing aging population. Older individuals are more prone to chronic constipation, so their rising numbers contribute to the increased demand for effective treatments. Additionally, advancements in medical technology, increased research and development activities, and the introduction of innovative therapies are driving market expansion. Moreover, supportive healthcare policies and reimbursement systems in various European countries further facilitate access to treatment options. The combination of these factors positions Europe as the fastest-growing region in the Chronic.

The current report Scope analyzes Chronic Constipation Treatment Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com

• North America (United States, Canada, Mexico)
• Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Switzerland, Luxembourg, Rest of Europe)
• Asia Pacific (China, Japan, South Korea, India, Australia, Singapore, Taiwan, South East Asia, Rest of APAC)
• Latin America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
• Middle East (Saudi Arabia, Turkey, UAE, Egypt, Qatar, Rest of Middle East)
• Africa (Nigeria, South Africa, Rest of Africa)

The above graph is for illustrative purposes only.

Chronic Constipation Treatment Market Analysis

Type Segment Analysis

The Normal-Transit Constipation type has secured the largest market share in the Chronic Constipation Treatment Market due to its prevalence among the population. This subtype, characterized by normal colonic transit time but difficulty passing stools, accounts for a significant portion of chronic constipation cases. As it represents a common form of the condition, there is a substantial demand for effective treatments catering to this subtype.

Market players have accordingly focused on developing therapies targeting the specific symptoms and underlying causes of Normal-Transit Constipation, contributing to its dominant position in the market share. Slow-Transit Constipation has attained the second-largest market share in the Chronic Constipation Treatment Market due to its significant prevalence and distinctive characteristics. This subtype is marked by delayed colonic transit, resulting in severe symptoms. Its distinct nature necessitates specialized treatment approaches, leading to a substantial demand for therapies tailored to address the specific challenges of Slow-Transit Constipation, thus contributing to its prominent market position.

• Normal-transit constipation
• Slow-transit constipation
• Others

The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Chronic Constipation Treatment Industry. Request a Free Sample PDF!

End-users Segment Analysis

Hospitals have secured the largest market share in the Chronic Constipation Treatment Market due to their role in handling complex and severe cases. Hospital settings offer specialized care, advanced diagnostics, and a range of treatment options, including surgical interventions. Patients with chronic constipation often require more intensive management, and hospitals provide the necessary expertise and resources, contributing to their dominant position in the market share.

Specialty clinics have gained the second-largest market share in the Chronic Constipation Treatment Market due to their focused expertise and tailored treatments. These clinics offer specialized care and comprehensive solutions for chronic constipation. Patients seeking personalized attention and treatments that align with their condition often prefer specialty clinics. This patient-centered approach contributes to the significant market position of specialty clinics.

• Hospitals
• Homecare
• Specialty Clinics
• Others

The above Graph is for representation purposes only. This chart does not depict actual Market share.

Chronic Constipation Treatment Therapy Type Segment Analysis

Pharmacological therapy has secured the largest market share in the Chronic Constipation Treatment Market due to its effectiveness and widespread acceptance. Pharmaceutical interventions offer direct and targeted relief for a variety of constipation subtypes. Patients and healthcare providers often prioritize medical treatments as they provide consistent and predictable results. The availability of a diverse range of pharmacological options, including laxatives and prescription medications, further contributes to its dominant market position.

Non-pharmacological therapy has gained the second largest market share in the Chronic Constipation Treatment Market due to its holistic approach and growing consumer preference for natural remedies. This category encompasses dietary modifications, exercise regimens, behavioral therapies, and more. With increasing awareness of lifestyle's impact on chronic constipation, individuals seek non-pharmacological solutions that address the root causes. The demand for personalized, side-effect-free interventions has propelled this market segment.

• Pharmacological Therapy
• Non-pharmacological Therapy

Chronic Constipation Treatment Treatment Type Segment Analysis

Due to its direct and targeted approach, medication treatment has secured the largest market share in the Chronic Constipation Treatment Market. Medications like laxatives and prescription drugs offer reliable relief for many constipation cases. Patients and healthcare providers often favor these solutions for their efficacy. The availability of various medication options and formulations further cements its dominant position in the market share.

Surgery has attained the second-largest market share in the Chronic Constipation Treatment Market due to its role in addressing severe and refractory cases. Surgical interventions such as colectomy or rectopexy are considered when other treatments prove ineffective. These procedures provide a more definitive solution for certain patients. As a result, surgery holds a significant market share for those requiring advanced interventions to manage chronic constipation.

• Medication
• Surgery

Chronic Constipation Treatment Drugs Segment Analysis

Receptor Agonist, Guanylate Cyclase-C Agonist, Laxatives, Stimulants and Others) Serotonin-4 (5-HT4) receptor agonists have secured the largest market share in the Chronic Constipation Treatment Market due to their targeted mechanism of action. By enhancing colonic motility and transit, these medications effectively alleviate constipation symptoms. Their specific mode of action and notable efficacy make them a preferred choice for treating various constipation subtypes. The demand for reliable and effective solutions contributes to their dominant market position.

Guanylate Cyclase-C (GC-C) agonists have gained the second largest market share in the Chronic Constipation Treatment Market due to their unique mechanism of increasing fluid secretion in the intestines and improving bowel movement. This distinct action makes them a valuable option for managing chronic constipation. Their targeted approach and efficacy in addressing specific constipation subtypes contribute to their significant market position.

• Serotonin-4 (5-Ht4) Receptor Agonist
• Guanylate Cyclase-C Agonist
• Laxatives
• Stimulants
• Others

Chronic Constipation Treatment Route of Administration Segment Analysis

The oral route of administration has secured the largest market share in the Chronic Constipation Treatment Market due to its convenience and patient preference. Oral medications are easy to consume, making them popular for individuals seeking consistent relief from constipation symptoms. This widely accepted and accessible delivery method has contributed to the dominance of the oral route in the market share.

The injectable route of administration has attained the second-largest market share in the Chronic Constipation Treatment Market due to its direct and rapid impact. Injectable formulations provide quick and targeted relief for severe cases or when other methods are ineffective. This mode of delivery is favored for its immediate effect, making it a significant player in the market share for chronic constipation treatment.

• Oral
• Injectable

Author's Detail

Manjiri Kanhere

Senior Research Associate at Cognitive Market Research

LinkedIn

Profile

Manjiri Kanhere is an experienced market researcher focused on the Pharma & Healthcare industry. With over 3+ years of experience, She has worked with major pharmaceutical companies and healthcare providers, helping them to understand market trends, identify new business opportunities, and develop effective sales & marketing strategies. Her expertise lies in the ability to analyze complex data sets and deliver insights that drive business decisions. At Cognitive Market Research, she handles the market research related to Pharma and healthcare industry.

Author's Conclusion